A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
Clinical trial NCT06927466 · RECRUITING
Trial details
- NCT number
- NCT06927466
- Sponsor
- Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-19
- Primary completion
- 2026-12-31
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.